June 27, 2026 02:06 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Ram Mandir Trust chief Champat Rai resigns as alleged donation siphoning row escalates | Ram Mandir fund row deepens: 8 arrested days after BJP called allegations 'false narrative' | 'Who tied the hands of CBI?': Calcutta HC on RG Kar case; victim's mother, now BJP MLA, says she is 'deeply disturbed' | Construction comes to a standstill at nearly 700 Kolkata projects after Taratala warehouse tragedy kills 15 | World Cup shocker! Ecuador stun Germany 2-1, storm into Round of 32 | Iran-US conflict: Cargo vessel hit near Strait of Hormuz, UN agency pauses evacuation operations | Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi | Taratala warehouse collapse: Death toll climbs to 8, five arrested as SIT launches probe | Oil prices crash, IndiGo takes off! Aviation and fuel stocks emerge as biggest winners | Passport is a travel document, not conclusive proof of citizenship: MEA
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.